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Abstract The regulation of phospholipase D1 (PLD1) by pro-
tein kinase C (PKC) isoforms was analyzed in human melanoma
cell lines. 12-O-Tetradecanoylphorbol-13-acetate (TPA)-in-
duced PLD1 activation was suppressed by the introduction of
PKCN as well as its kinase-negative mutant in MeWo cells,
which contain PKCK but lack PKCL. PLD activity was not
a¡ected by PKCN in G361 cells, which have PKCL but are
de¢cient in PKCK. In MeWo cells introduced by PKCK and
PLD1, the association of these proteins was observed, which
was enhanced by the TPA treatment. In cells overexpressing
PKCN in addition to PKCK and PLD1, TPA treatment in-
creased the association of PKCN and PLD1, while it attenuated
the association of PKCK and PLD1. These results indicate that
PKCN inhibits TPA-induced PLD1 activation mediated by
PKCK through the association with PLD1.
/ 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
Key words: Phospholipase D; Protein kinase C;
12-O-Tetradecanoylphorbol-13-acetate;
Protein^protein interaction; Adenovirus vector;
Melanoma cell
1. Introduction
Phospholipase D (PLD) catalyzes the hydrolysis of phos-
phatidylcholine to generate phosphatidic acid and choline,
and its catalytic activity is regulated by a variety of agonists
through heterotrimeric G protein-coupled and tyrosine ki-
nase-type membrane receptors [1^4]. Phosphatidic acid and
its dephosphorylated product, diacylglycerol, are important
second messengers, and thus PLD is recognized to play a
crucial role in the signal transduction. In mammals, two dif-
ferent PLD genes, PLD1 and PLD2, have been identi¢ed,
which are expressed in many cell types. The regulation mech-
anism for PLD1 has been studied extensively, and protein
kinase C (PKC) is proposed to mediate the link between re-
ceptor stimulation and PLD1 activation. PKC consists of
multiple isoforms that are classi¢ed into three groups in mam-
mals, cPKC (K, LI, LII, and Q), nPKC (N, O, R, and a), and
aPKC (j and V) based on structural characteristics [5^6]. The
cPKC and nPKC isoforms are activated by diacylglycerol
produced from receptor-mediated hydrolysis of inositol phos-
pholipids, and are the prime targets of tumor-promoting
phorbol esters such as 12-O-tetradecanoylphorbol-13-acetate
(TPA). The K and N isoforms of the cPKC and nPKC groups,
respectively, are expressed universally among the cells and
tissues.
The role of PKC in the regulation of PLD1 was implicated
by studies that phorbol ester stimulates PLD activity, and that
PKC inhibitors suppress the activation of PLD in intact cells
[4]. Among the PKC isoforms, PKCK and PKCL were iden-
ti¢ed to enhance PLD activity in response to TPA and recep-
tor stimulation in cells [7^10]. On the other hand, activation
of PLD1 was revealed to be independent of the protein kinase
activity of PKC [11^13]. We have recently reported that PLD1
is dually regulated by the cPKC isoforms K and L through
phosphorylation as well as via a protein^protein interaction
using the human melanoma cell lines MeWo and G361, the
former contains PKCK but lacks PKCL and the latter has
PKCL but is de¢cient in PKCK [14].
Furthermore, Hornia et al. [15] have reported that PKCN of
the nPKC group controls PLD activity in intact cells. They
show that rottlerin, an inhibitor of PKCN, as well as the ex-
pression of a dominant-negative mutant of PKCN, increases
PLD activity in rat 3Y1 ¢broblasts overexpressing the epider-
mal growth factor (EGF) receptor. Based on these results,
they proposed that PLD activity is attenuated by PKCN
through phosphorylation upon EGF treatment. In this study,
we investigated the involvement of PKCN in the regulation of
PLD1 using the melanoma cell lines, and revealed that PKCN
suppresses PKCK-mediated activation of PLD1 in a manner
independent of its protein kinase activity.
2. Materials and methods
2.1. Cell culture
Human melanoma MeWo and G361 cells were obtained from the
Japanese Cancer Research Resources Bank (Tokyo, Japan), and cul-
tured in Eagle’s minimal essential medium supplemented with 10%
fetal calf serum.
2.2. Adenovirus vectors
The full-length rat PLD1 cDNA [16] was cloned into the pCMV5
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vector with a FLAG-epitope tag to make the amino-terminally
FLAG-epitope-tagged PLD1 (FLAG-PLD1). Recombinant adenovi-
rus vectors of FLAG-PLD1, rabbit PKCK [17], mouse PKCN [18], and
a kinase-negative mutant of PKCN replacing Lys-376 in the ATP-
binding site by Ala (KN-PKCN) [19] were prepared as described pre-
viously [14,20]. The cDNA clones of each PKC isoform from di¡erent
mammalian species encode almost identical deduced amino acid se-
quences, and thus each PKC isoform is regarded to have properties
indistinguishable among the species [5,6]. The adenovirus vectors con-
taining FLAG-PLD1, PKCK, PKCN, and KN-PKCN were designated
AxPLD1, AxPKCK, AxPKCN, and AxKN-PKCN, respectively. The
adenovirus designated AxLacZ carrying the L-galactosidase gene
(LacZ) from Escherichia coli [21] was used as a control virus.
2.3. Reverse transcription-polymerase chain reaction (RT-PCR)
Total RNA (2 Wg) was reverse transcribed by using SuperScript II
(Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s
protocol. The following human PLD1-speci¢c primers [22] were
used: 5P-TGGGCTCACCATGAGAA-3P (sense) and 5P-GTCATGC-
CAGGGCATCCGGGG-3P (antisense). PCR was conducted in PCR
Thermal Cycler MP (TaKaRa, Tokyo, Japan) in a 50 Wl reac-
tion volume using Hot Star Taq (Qiagen, Valencia, CA, USA). Re-
action conditions were as follows: 94‡C for 1 min, 55‡C for 1 min,
and 72‡C for 1.5 min for 35 cycles. An aliquot sample of each reaction
(10 Wl) was analyzed in 2% agarose gel and visualized by ethidium
bromide £uorescence staining. Molecular weight markers (Promega,
Madison, WI, USA) were used to estimate the size of the ampli¢ed
fragments.
2.4. PLD assay
PLD activity was assayed by monitoring the in vivo transphospha-
tidylation activity as described previously [14]. Brie£y, cells in six-well
culture plates were infected with various plaque-forming units (PFU)/
cell of adenovirus for 24 h, and then labeled with 1-[1-14C]palmitoyl-2-
lyso-sn-glycero-3-phosphocholine (54.0 mCi/mmol, Amersham Phar-
macia Biotech, Buckinghamshire, UK) (0.25 WCi/107 cells) for 16 h.
Then, cells were stimulated with 100 nM TPA (Sigma, St. Louis, MO,
USA) in the presence of 1% ethanol for 30 min, and the lipids were
extracted and applied to thin layer chromatographic analysis. Radio-
activity was quantitated by a Bioimaging analyzer (BAS 2000; Fuji
Film, Tokyo, Japan), and PLD activity was expressed as a percentage
of the radioactivity in phosphatidylethanol (PtdEtOH) relative to the
total lipid radioactivity found in a given lane. Data are expressed as
the meanTS.E.M. (n=3).
2.5. Immunoprecipitation and immunoblot analysis
Cells plated out in 10-cm tissue dishes were treated as for the PLD
assay described above except for the labeling with the radioactive
lipid. Immunoprecipitation and immunoblot analysis were carried
out essentially as described previously [14]. Brie£y, the cells were lysed
in 20 mM Tris^HCl (pH 7.5) containing 1 mM EDTA, 1 mM EGTA,
10 mM 2-mercaptoethanol, 1% Triton X-100, 150 mM NaCl, 10 mM
NaF, 1 mM sodium orthovanadate, and 50 Wg/ml phenylmethylsul-
fonyl £uoride. The cell extract was incubated for 3 h at 0^4‡C with the
antibody against either PKCK (Santa Cruz Biotechnology, Santa
Cruz, CA, USA) or PKCN (Transduction Laboratories, Lexington,
KY, USA). Then, protein A-Sepharose (Pharmacia Biotech, Uppsala,
Sweden) was added to the mixture and incubated for 1 h at 0^4‡C
with constant mixing. In the case of immunoprecipitation of FLAG-
PLD1, anti-FLAG M2 a⁄nity gel (Sigma) was employed instead of
protein A-Sepharose. Where indicated, control mouse IgG (Wako
Pure Chemical Industries, Osaka, Japan) or protein A-Sepharose
incubated with control mouse IgG was used. The immunoprecipi-
tated proteins were separated by sodium dodecyl sulfate^polyacryl-
amide gel electrophoresis and transferred onto an Immobilon P
membrane (Millipore, Bedford, MA, USA). Immunoblot analysis
was carried out using antibodies against PKCK, PKCL (Transduc-
tion Laboratories), PKCN, and FLAG-epitope tag (M2, Sigma) as
the primary antibodies. The alkaline phosphatase-conjugated anti-
mouse antibody (Promega) was employed as the secondary antibody
using 5-bromo-4-chloro-3-indolyl-phosphate and nitroblue tetrazo-
lium as substrates. Where indicated, the lysates from melanoma cells
were directly subjected to immunoblot analysis, and rat brain lysate
(Transduction Laboratories) was employed as a marker of PKC iso-
forms.
3. Results and discussion
It has been reported that the melanoma cell lines MeWo
and G361 express PKCK and PKCL of the cPKC, respectively
[23]. In contrast, PKCN was detected in both these melanoma
cells (Fig. 1A). The expression of PLD1 in MeWo and G361
cells was investigated by RT-PCR (Fig. 1B). The speci¢c
primers to human PLD1 ampli¢ed two sequence signals of
533 and 638 bp from both cell lines. These bands derive
from the alternatively spliced forms of human PLD1a and
PLD1b, respectively [22]. The role of PKCN in the regulation
of PLD activation was examined in these melanoma cell lines
(Fig. 2). Without the infection of adenovirus vector for PKCN,
the basal levels of PtdEtOH, the PLD reaction product, were
similar in both melanoma cell lines, and the TPA treatment
induced PLD activation more e⁄ciently in MeWo cells than
in G361 cells (Fig. 2A), as described previously [14]. In MeWo
cells, the introduction of PKCN using the adenovirus vector
suppressed the TPA-stimulated PLD activity in a dose-depen-
dent manner, whereas the TPA-stimulated phospholipase ac-
tivity was not a¡ected by the introduction of PKCN in G361
cells. In G361 cells infected with adenovirus vector for PKCK,
the introduction of PKCN attenuated the elevation of PLD
activity stimulated by TPA (Fig. 2B). These results indicate
that PKCN prevents PLD1 activation mediated by PKCK.
PKCK is revealed to regulate PLD1 through phosphoryla-
tion as well as via a protein^protein interaction in vivo [14].
Therefore, the mechanism for suppression of PLD1 activation
by PKCN was analyzed by expressing KN-PKCN in MeWo
cells (Fig. 3). Introduction of PKCK strongly elevated the
basal and TPA-stimulated PLD activity as described previ-
ously [18], and this potentiation was suppressed by co-intro-
duction with PKCN as well as KN-PKCN (Fig. 3A). KN-
PKCN attenuated the elevation of TPA-stimulated PLD activ-
ity even more e⁄ciently than the wild type enzyme. In the
cells overproducing PLD1, PLD activity was increased and
the introduction of PKCN and KN-PKCN showed almost
identical e¡ects on PLD activity as in the cells without infec-
tion of adenovirus vector for PLD1 (Fig. 3B). The protein
levels of the recombinant PLD1 were, however, not altered
by overexpression of PKCN and KN-PKCN. These results sup-
port that the attenuation of the elevation of PLD activity in
these cells re£ects suppression of PKCK-mediated PLD1 acti-
vation rather than the reduction of the PLD1 protein levels.
Fig. 1. PKC isoforms and PLD1 in melanoma cell lines. A: Cell ly-
sates of melanoma cells were subjected to immunoblot analysis us-
ing antibodies against either PKCK, PKCL, or PKCN. Rat brain ly-
sate was used as a positive control. B: Total RNA prepared from
melanoma cells was subjected to RT-PCR using speci¢c primers for
human PLD1. The control lane without the template is indicated as
(3). The sizes of the molecular weight markers are shown in bp,
and the positions of the ampli¢ed fragments are indicated by ar-
rows.
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Thus, PKCN was concluded to repress the PKCK-mediated
elevation of PLD activity in a manner independent of its
protein kinase activity. Goerke et al. [24] have shown that
TPA induces apoptosis in A7r5 vascular smooth muscle cells
overexpressing the wild type PKCN as well as KN-PKCN. It is
therefore plausible that PKCN can have physiological roles
that are independent of its catalytic activity, and thus are
likely to be occurring through protein^protein interaction.
Hornia et al. [15] have reported that the expression of a dom-
inant-negative mutant of PKCN elevates PLD activity in the
¢broblast cell line. The mutant in their study should have
behaved simply as a kinase-negative molecule rather than pre-
venting the role of endogenous PKCN for the regulation of
PLD1. It is known that dominant-negative mutants of PKC
isoforms show a broad speci¢city [25]. For example, the dom-
inant-negative mutant of PKCN generated by replacing its
Fig. 2. E¡ect of overexpression of PKCN on TPA-induced PLD activation. A: MeWo (left) and G361 (right) cells were infected with di¡erent
PFU/cell of AxPKCN. The expression of PKCN was examined by immunoblot analysis after immunoprecipitation using the antibody against
PKCN. B: G361 cells were infected with AxPKCK and AxPKCN. PLD activity was assayed after incubation in the presence (solid bar) and ab-
sence (open bar) of TPA.
Fig. 3. Suppression of TPA-induced PLD activation by overexpression of PKCN and KN-PKCN. MeWo cells were infected with AxPKCK,
AxPKCN, and AxKN-PKCN in the presence (A) or absence (B) of AxPLD1. The expressions of PKCK, PKCN and KN-PKCN, and PLD1 were
examined by immunoblot analysis after immunoprecipitation by using the antibodies against PKCK, PKCN, and FLAG-epitope tag, respec-
tively. PLD activity was assayed after incubation in the presence (solid bar) and absence (open bar) of TPA.
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phosphorylation motif sites is capable of inhibiting PKCK
activity. In a previous study, however, the kinase-negative
PKCK was revealed to enhance PLD activity as the wild
type PKCK [14]. Thus, it is less possible that the kinase-neg-
ative PKCN prevents the role of PKCK, because the kinase-
negative PKCK itself does not work as a dominant-negative.
The kinase-negative PKC isoforms employed in this study
replacing the Lys residue in the ATP-binding site may have
a property distinct from that of the molecules mutating the
phosphorylation motif sites.
To analyze further the mechanism of PLD inhibition by
PKCN, the association of the PKC isoforms with PLD1 was
examined in MeWo cells infected with adenovirus vectors
(Figs. 4 and 5). In cells co-introduced with PKCK and
PLD1, PKCK was detected in the immunoprecipitate of
PLD1 and this association was increased upon TPA stimula-
tion (Fig. 4A). The result was con¢rmed by the immunopre-
cipitation of PKCK followed by immunoblot analysis using
anti-FLAG antibody (Fig. 4B). E¡ect of PKCN on the inter-
action of PKCK and PLD1 was studied by introducing PLD1,
PKCK, and PKCN simultaneously in MeWo cells (Fig. 5). Not
only PKCK but also PKCN was associated with PLD1 in the
TPA-treated cells, and a high dose of the PKCN vector de-
creased the interaction of PKCK with PLD1, while association
of PKCN with PLD1 further increased in the cells. In the cells
overexpressing PKCK, PKCN, and PLD1, the association of
PLD1 and PKC isoforms was observed in cells in the absence
of TPA stimulation (Figs. 4 and 5). Complex formation of
PKCK and PLD1 has been demonstrated in unstimulated ¢-
broblasts [26]. A part of the PLD1 molecules endogenously
expressed in cells may associate with PKC isoforms under
resting conditions.
It is established that PKCK is a common and predominant
regulator of PLD1, which activates the phospholipase through
mechanisms dependent on and independent of phosphoryla-
tion. In the present study, we investigated the role of PKCN in
the regulation of PLD1. It was revealed that PKCN suppresses
PKCK-mediated PLD1 activation through protein^protein in-
teraction with PLD1. It is interesting to assume that PLD1 is
free from both PKCK and PKCN in unstimulated cells, and
PKCK associates with PLD1 whereas PKCN prevents the
binding in a competitive manner upon treatment of the cells
with agonists. Another possibility is that PLD1 is associated
with PKCN even under resting conditions, and cell stimulation
induces the binding of PKCK to PLD1. On the other hand,
these two PKC isoforms, which are both expressed ubiqui-
tously among various cells [5,6], have been reported to have
opposite e¡ects on cell growth and apoptosis [27]. It may be a
common way that PKCK and PKCN contribute distinctly to
various signaling processes.
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Fig. 4. Association of PKCK to PLD1 in MeWo cells. The cells co-
infected with AxPKCK and AxPLD1 were incubated in the presence
or absence of TPA. A: The cell lysates were subjected to immuno-
precipitation (IP) using the anti-FLAG M2 a⁄nity gel (Anti-FLAG)
and immunoblot analysis (IB) was carried out using the antibodies
against either PKCK (Anti-PKCK) or FLAG (Anti-FLAG). B: The
cell lysates were subjected to immunoprecipitation (IP) using the
antibody against PKCK (Anti-PKCK) and immunoblot analysis (IB)
was carried out using the antibodies against either FLAG (Anti-
FLAG) or PKCK (Anti-PKCK). Control mouse IgG or control
mouse IgG coupled with protein A-Sepharose (Control IgG) was
employed as a control. The results shown are representative of three
independent experiments.
Fig. 5. Association of PKCN with PLD1 in MeWo cells. The cells
co-infected with AxPKCK, AxPLD1 and di¡erent doses of AxPKCN
were incubated in the presence or absence of TPA. The association
of PKC isoforms with PLD1 was analyzed as in Fig. 4.
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